Consequently, the suppression of ILF3 resulted in decreased PD-L1, enhancing the cytotoxicity of activated CD8+ T cells toward GC cells, which triggered an immune response and played a therapeutic role in GC. This evidence concerns the gene ILF3 and gastric cancer.